HR+ breast cancer updates from #ASCO2026 📊
@DrSGraff shares insights on new data shaping early-stage care, targeted therapy, and surgical decisions. OPTIMA, NATALEE, and more. Watch now ⬇️ https://t.co/OXHJl8cxE2
OPTIMA prelim: Prosigna test identified a group of patients (22%) who had adverse outcomes despite low Oncotype DX recurrence score tumours
#ESMOBreast25@myESMO
Today at #ESMOBreast25: 10-year OPTIMA PRELIM clinical outcomes presented. Findings show #Prosigna breast cancer assay better classified patients' risk of recurrence as compared to the test used to initially assign patients to treatment groups. Results from this early feasibility study contributed to Prosigna's selection for the ongoing 4500-patient prospective OPTIMA trial.
View Presentation: https://t.co/Zgcg9SH3PO
Important Note: https://t.co/tltSRBtiSL
@Nafussa @TapNewsAgency@UE@publiceye_ch The higher rates in Egypt, and North Africa generally, has been linked to the proximity with the Nile delta region where S. Hematobium infection is widespread, and increased cigarette smoking
The hardest #top10 (ish) I’ve ever done for a meeting: the amount of critical data that will be presented at #SABCS22 is impressive. Novel drugs, important trial updates, highly awaited biomarker data, new paradigms. Make sure not to miss what promises to be a remarkable SABCS!
Découvrez le débat d'experts sur les "Actualités dans les Cancers du Sein-et signatures génomiques" avec G. Freyer, F. Penault-Llorca et O. Tredan
-> https://t.co/BarCqIx4Bf
#cancerdusein#senologie#génomiques#TKO
@sasoukee اللطف عليكم. On n’y pense pas assez mais les virus aussi peuvent provoquer le cancer. Le lien de causalité reste difficile à établir https://t.co/D8J4W0FgAG
During #BreastCancerAwarenessMonth, Veracyte is releasing new educational tools dedicated to #BreastCancer patients. We are committed to help you better inform your patients about the Prosigna Breast Cancer Assay.
Are you a physician who is interested in learning more about the latest highlights in molecular gene expression testing? If so, join us on Sept. 27 for our webinar on the history and evolution of PAM50 & Veracyte's #Prosigna Breast Cancer Prognostic Gene Signature Assay.
Our expanded #Prosigna Breast Cancer Assay website has launched! Visit the site to learn how the Prosigna second-generation test can more comprehensively inform treatment decisions for patients with early-stage #BreastCancer.
Le @Senat adopte 2 avancées essentielles que nous portons: suppression du questionnaire de santé pour les les emprunts jusqu’à 250.000€, #droitaloubli réduit à 5 ans pour TOUS malades de #cancer. Merci au rapporteur Mr Gremillet pour l’écoute &la qualité de son travail.
1) Bon arrêtons avec le discours médical bienveillant et paternaliste/maternaliste. Nous ne pourrons pas atteindre le Zéro COVID en France ou ailleurs d’ailleurs, sans une vision mondiale… nous en sommes très loin, car c’est une pandémie !
A tous ceux qui craignent pour leur ADN, l'ARNm code juste pour la protéine immunogène et n'affecte pas votre ADN. Savez-vous que le tabagisme induit 1000 à 10000 mutations dans l'ADN des cellules bronchiques saines ? https://t.co/y9eFaf0GYK